Antibody-drug conjugate · Cytotoxic, directed at G-protein coupled receptor family C group 5 member D (GPRC5D) · developed by ASTRAZENECA
Vemzatatug vedotin (AZD0305) is an antibody-drug conjugate in which an anti-GPRC5D monoclonal antibody is linked to the microtubule-disrupting agent MMAE. After the antibody binds GPRC5D on tumor cells and the complex is internalized, MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis. It is studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
Multiple Myeloma
Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →